Andrew Nicholson, MD
Family Medicine · Gorham, MENPI 1295912665
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,311 of the $2,806 with a category attached, or 82.4%. It is spread thinly across 20 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $25.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$648
- Astellas Pharma US Inc$489
- GSK$320
- Boehringer Ingelheim$243
- AbbVie$191
- Lilly USA, LLC$158
- plus $757 from 14 others
What the payments were for
- Food & beverage$2,31182%
- Education$49418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 29 | $648 |
| Astellas Pharma US Inc | 6 | $489 |
| GSK | 14 | $320 |
| Boehringer Ingelheim | 13 | $243 |
| AbbVie | 5 | $191 |
| Lilly USA, LLC | 5 | $158 |
| Pfizer | 8 | $154 |
| Merck | 5 | $105 |
| Sunovion Pharmaceuticals Inc. | 5 | $103 |
| Corcept Therapeutics | 4 | $71 |
| Bayer | 4 | $65 |
| Johnson & Johnson | 3 | $61 |
| Dexcom, Inc. | 2 | $53 |
| Gilead | 1 | $27 |
| Verona Pharma, Inc. | 1 | $26 |
| Braeburn Inc. | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Indivior Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,806 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 40 | $56,964 |
| JardianceEmpagliflozin | 24 | $40,224 |
| EliquisApixaban | 22 | $31,306 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $29,738 |
| FarxigaDapagliflozin Propanediol | 20 | $27,829 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $19,146 |
| JanuviaSitagliptin Phosphate | 11 | $18,718 |
| MounjaroTirzepatide | 15 | $17,974 |
| XareltoRivaroxaban | 13 | $16,981 |
| OxycontinOxycodone Hcl | 13 | $13,186 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $6,767 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 72 | $5,115 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 13 | $4,805 |
| Atorvastatin Calcium | 186 | $1,874 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 76 | $1,792 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $158 | $74,93855 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $648 | $51,78051 claims |
| Boehringer IngelheimJardiance | $243 | $40,22424 claims |
| PfizerEliquis | $154 | $31,30622 claims |
| GSKTrelegy Ellipta | $320 | $29,73825 claims |
| MerckJanuvia | $105 | $18,71811 claims |
| Johnson & JohnsonXarelto | $61 | $16,98113 claims |
| Indivior Inc.Suboxone | $15 | $6,76713 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $21 | $5,11572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Gorham
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
- Julia McDonaldAugusta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.